Saponin QA-21V1: all 29 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ TransplantsRecruitingNCT06741072Phase 1
- RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEVRecruitingNCT06484335Phase 1
- Safety and Immunogenicity of CJCV2 With and Without ALFQCompletedNCT05500417Phase 1Results posted
- A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedNCT00960531Phase 2Results posted
- Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00955409Phase 2Results posted
- Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00498602Phase 2Results posted
- Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00479557Phase 2Results posted
- Vaccine Therapy and QS21 in Treating Patients With Metastatic Breast CancerCompletedNCT00470574Not applicableResults posted
- Vaccine Therapy in Treating Patients at High Risk for Breast Cancer RecurrenceCompletedNCT00030823Not applicableResults posted
- Vaccine Therapy in Treating Patients With Metastatic MelanomaCompletedNCT00003224Phase 1Results posted
- Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV RemissionWithdrawnNCT05769569Phase 1
- PHASE 1 SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19CompletedNCT04784767Phase 1
- HIV Vaccine in HIV-uninfected AdultsCompletedNCT04658667Phase 1
- A Trial For The Study of Falciparum Malaria Protein 014 Administered Via Intramuscular Injection in Healthy AdultsStatus unknownNCT04296279Phase 1
- A Trial For The Study of Falciparum Malaria Protein 013 Administered Via Intramuscular Injection in Healthy AdultsStatus unknownNCT04268420Phase 1
- Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate CancerCompletedNCT00579423Phase 2
- Vaccine Therapy Plus QS21 in Treating Patients With Prostate CancerCompletedNCT00036933Phase 1
- Vaccine Therapy Plus QS21 in Treating Patients With Advanced Pancreatic or Colorectal CancerCompletedNCT00006387Phase 1
- Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal CancerCompletedNCT00006041Phase 1
- Vaccine Therapy in Treating Patients With Primary Stage II MelanomaStatus unknownNCT00005052Phase 3
- Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate CancerCompletedNCT00004929Phase 1
- Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial TherapyCompletedNCT00004249Phase 2
- Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate CancerCompletedNCT00003819Phase 1
- Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced MelanomaCompletedNCT00003362Phase 2
- Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of DiseaseCompletedNCT00003357Phase 1
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected AdultsCompletedNCT00001096Phase 1
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy AdultsCompletedNCT00001052Phase 1
- A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.CompletedNCT00001044Phase 1
- Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected WomenWithdrawnNCT00000809Phase 1